Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
AUPH

Prezzo Aurinia Pharmaceuticals

AUPH
$0
+$0(0,00%)
Nessun dato

*Data last updated: 2026-04-28 23:33 (UTC+8)

As of 2026-04-28 23:33, Aurinia Pharmaceuticals (AUPH) is priced at $0, with a total market cap of $2,13B, a P/E ratio of 7,46, and a dividend yield of 0,00%. Today, the stock price fluctuated between $0 and $0. The current price is 0,00% above the day's low and 0,00% below the day's high, with a trading volume of 823,22K. Over the past 52 weeks, AUPH has traded between $0 to $0, and the current price is 0,00% away from the 52-week high.

AUPH Key Stats

Yesterday's Close$16
Market Cap$2,13B
Volume823,22K
P/E Ratio7,46
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)2,13
Net Income (FY)$287,20M
Revenue (FY)$283,05M
Earnings Date2026-05-11
EPS Estimate0,18
Revenue Estimate$76,97M
Shares Outstanding130,29M
Beta (1Y)1.523

About AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
SectorHealthcare
IndustryBiotechnology
CEOKevin C. Tang
HeadquartersEdmonton,BC,CA
Official Websitehttps://www.auriniapharma.com
Employees (FY)128,00
Average Revenue (1Y)$2,21M
Net Income per Employee$2,24M

Aurinia Pharmaceuticals (AUPH) FAQ

What's the stock price of Aurinia Pharmaceuticals (AUPH) today?

x
Aurinia Pharmaceuticals (AUPH) is currently trading at $0, with a 24h change of 0,00%. The 52-week trading range is $0–$0.

What are the 52-week high and low prices for Aurinia Pharmaceuticals (AUPH)?

x

What is the price-to-earnings (P/E) ratio of Aurinia Pharmaceuticals (AUPH)? What does it indicate?

x

What is the market cap of Aurinia Pharmaceuticals (AUPH)?

x

What is the most recent quarterly earnings per share (EPS) for Aurinia Pharmaceuticals (AUPH)?

x

Should you buy or sell Aurinia Pharmaceuticals (AUPH) now?

x

What factors can affect the stock price of Aurinia Pharmaceuticals (AUPH)?

x

How to buy Aurinia Pharmaceuticals (AUPH) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

AUPH
CFD
Fai trading

Hot Posts su Aurinia Pharmaceuticals (AUPH)

MrDecoder

MrDecoder

03-27 18:47
Keeping tabs on the quarterly activity of billionaire superinvestors can be a great way to unearth hidden gems, or perhaps avoid potential potholes. Billionaires, after all, are rich for a reason. When it comes to the complex but rewarding area of healthcare, Baker Brothers Advisors, a hedge fund run by billionaire brothers Felix and Julian Baker, is without question the best in the game at picking big winners in this volatile sector. While Felix and Julian Baker haven't always been spot on with their healthcare stock picks, they have hit the jackpot numerous times over the years. Some of their best picks to date include top growth stocks like **Axsome Therapeutics**, **Exact Sciences**, and **GW Pharmaceuticals plc**. So when the Baker Brothers start to pour money into a little known healthcare company, it's probably a good idea to take note.  Which relatively unknown stocks have the Baker Brothers been quietly gobbling up in 2020? The fund recently disclosed massive buys in **Aurinia Pharmaceuticals** (AUPH 3.22%), **Kodiak Sciences** (KOD +9.76%), and **Zymeworks** (ZYME 0.85%). Are these biotech growth stocks suitable for everyday investors? Let's dig deeper to find out.    Image source: Getty Images. Aurinia: A compelling growth story ---------------------------------- Aurinia's shares were up by nearly 200% before the COVID-19-induced sell-off. The company's stock has been blasting higher of late in response to the strong showing of its experimental lupus nephritis drug, voclosporin, in a pivotal stage trial. Lupus nephritis is characterized by swelling of the kidneys in patients, mostly women, afflicted with the autoimmune disorder systemic lupus erythematosus. By Aurinia's own estimates, voclosporin would target around 220,000 patients in the United States for this first indication. However, the company also has plans to eventually broaden the drug's label to include both dry eye syndrome and focal segmental glomerulosclerosis, another kidney ailment. The key info is that voclosporin could generate peak sales of approximately $770 million as a treatment for just lupus nephritis. But if Aurinia can successfully add on these two other indications, the drug's peak sales may even top $1.6 billion by the end of the decade. That's quite a haul for a company with a market cap of $1.7 billion at present.  What's the opportunity? From an organic sales standpoint, Aurinia's growth story may take a few years to kick into high gear. Most early-commercial-stage biopharmas, after all, tend to struggle to generate sales right out of the gate because of a lack of infrastructure, networking experience, and limited financial resources. The good news is that Aurinia will probably never have to worry about the commercial side of the equation. Aurinia should either attract an eager marketing partner or a full-on takeover bid within the next 12 months, assuming voclosporin sails through its upcoming regulatory review in the United States. That's not a guaranteed outcome, to be sure. But voclosporin is exactly the type of well-differentiated, high-value asset that tends to attract buyers in the world of pharmaceuticals. So if you're comfortable with the risk associated with binary regulatory decisions, Aurinia's stock should definitely be on your radar right now. This stock could easily double by the end of the year, after all.     Kodiak: More room to run ------------------------ Kodiak Sciences was one of the best-performing stocks last year, thanks to its experimental wet age-related macular degeneration drug KSI-301. In fact, KSI-301's early-stage results were so impressive that the Baker Brothers decided to strike up a $225 million capped royalty deal with Kodiak. That's certainly an unusual development for a drug that's still a few years away from reaching the market. But it does underscore KSI-301's enormous commercial potential. In short, this experimental eye medication could possibly rack up $3 billion to $4 billion in annual sales by 2030.     What's the big deal? Most commercial-stage biopharma stocks trade at no less than three times the peak sales estimates of their flaghship products. So on the low end, Kodiak's shares appear more than capable of gaining another 300%, from current levels, within a few short years. Now, there is still quite a bit of clinical and regulatory risk on the table with this stock. But Kodiak's jaw-dropping upside potential should definitely appeal to the risk-tolerant crowd.   **Zymeworks: A top cancer play** -------------------------------- Zymeworks designs and trials cancer-fighting antibodies. The company's shares have been soaring over the past year because of a number of top-flight partnerships with several big pharmas, a large equity financing that shored up its balance sheet, and the steady progress of its lead HER2-positive cancer therapies called ZW25 and ZW49, respectively. Still, Zymework's shares may be an outright steal at current levels, even after the stock's recent run. Point blank: The company's market cap of $1.72 billion doesn't reflect the ginormous commercial potential of its clinical pipeline in any way.  What's the risk? Zymeworks is targeting a number of hard-to-treat malginancies, and its pipeline won't produce a commercial-stage product anytime soon. That said, the company's robust pipeline of novel antibodies could attract a suitor in the not-so-distant future. Big pharma has already shown a strong interest in the company's anti-cancer platform, after all. Driving this point home, oncology companies with well-differentiated assets in early- to mid-stage development have consistently been some of the most attractive buyout targets for a number of years now. In all, Zymeworks is a risky biotech stock, to be sure, but the company does have a lot to offer growth-oriented investors.
0
0
0
0
CoffeeNFTs

CoffeeNFTs

03-24 23:46
IBD stock screens are regularly updated to add new stocks to watch, as well as weed out those that have started to show weakness. In the tables below, you'll see which stocks like **ASML Holding** (ASML) have been added to or removed from lists like the IBD 50, Sector Leaders and the IBD Big Cap 20. ASML makes a type of chipmaking equipment that is in high demand by AI chipmakers, memory chipmakers and others. No other company in the world has the technology ASML does. Tuesday ASML climbed 2.2% and joined the flagship IBD 50. Another AI play, contract chipmaker **Taiwan Semiconductor** (TSM) was the only company that qualified for Sector Leaders. ↑ X This video file cannot be played.(Error Code: 102630) Stock Market Exposure: How To Make Incremental Portfolio Management Decisions See All Videos NOW PLAYING Stock Market Exposure: How To Make Incremental Portfolio Management Decisions Other top-notch stocks making it onto various best stock lists include energy equipment maker **Forgent Power Solutions** (FPS). Also, animal health stock **Phibro Animal Health** (PAHC) and gold mining firm **Franco Nevada** (FNV). All told, 16 stocks qualified for a spot on IBD watchlists. The screens are based on The IBD Methodology. This strategy looks for stocks displaying the common traits typically shared by the best-performing stocks in the early stages of their big price moves. Check this column each day to help build and maintain your list of stocks to watch with alerts to the most recent changes. ASML Stands Alone In Chipmaker Realm ------------------------------------ The extreme ultraviolet (EUV) lithography machines ASML makes imprint silicon wafers with silicon designs. Those designs are for various semiconductors including artificial intelligence chips. No other chip equipment maker has been able to duplicate the advanced EUV technology ASML has. But never buy a stock just because it's on an IBD list. Be sure to do your own research and run all your stock ideas through a buying checklist. And you can use IBD's simple three-step routine to quickly track general market trends, find stocks to watch, and pinpoint the best time to buy and sell. Changes made as of March 24, 2026 5:50 PM ET. IBD 50: ASML Among 9 Rising Onto The 50 --------------------------------------- Shares of Dutch chip gear maker ASML hit a record high on Feb. 25. It slid to a 1,276.11 low in early March and rebounded. It closed at 1399.42 Tuesday, up 2.2% for the day. IBD's flagship screen of the best growth stocks to watch gives you 50 companies showing strong relative price strength and top-notch fundamentals. Before you decide what stocks to buy, always check out these new and innovative stocks that historically far outperform the S&P 500. * View All IBD 50 Stocks And Related Analysis * Check out the Innovator IBD 50 ETF (FFTY) | **Added To IBD 50** | | | --- | --- | **Removed From IBD 50** | | | ASML | (ASML) | Arista Networks | (ANET) | | Ensign | (ENSG) | CAVA Group | (CAVA) | | Five Below | (FIVE) | Canadian Imperial Bank of Commerce | (CM) | | Hubbell | (HUBB) | DigitalOcean Holdings | (DOCN) | | Howmet Aerospace | (HWM) | Hannon Armstrong Sustainable Infrastructure | (HASI) | | ITT | (ITT) | MDA Space | (MDA) | | OneSpaWorld Holdings | (OSW) | Micron Technology | (MU) | | Sprott Inc | (SII) | Oneok | (OKE) | | Woodward | (WWD) | SQM | (SQM) | IBD Newsletters --------------- #### Get exclusive IBD analysis and actionable news daily. SIGN UP NOW! IBD Newsletters --------------- #### Get exclusive IBD analysis and actionable news daily. * How To Invest * Market Prep * Tech Report Please enter a valid email address Please select a newsletter GO Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use x Thank You! ---------- #### You will now receive IBD Newsletters ALL DONE! Something Went Wrong! --------------------- #### Please contact customer service CLOSE IBD Sector Leaders ------------------ IBD's most stringent and powerful screen, IBD Sector Leaders highlight the best growth stocks in IBD's 33 sectors. All IBD Sector Leaders show outstanding earnings and sales growth in recent quarters and are strong across many other fundamental and price-performance metrics. * View All IBD Sector Leaders Stocks And Related Analysis | **Added To IBD Sector Leaders** | | | --- | --- | **Removed From IBD Sector Leaders** | | | Taiwan Semiconductor | (TSM) | Arista Networks | (ANET) | IBD Big Cap 20: Gold Still Among Hottest Markets ------------------------------------------------ Gold mining firm Franco Nevada boasts a best-possible 99 IBD Composite Rating, indicating it's among the top 1% of stocks for price performance this past year. This daily screen uncovers top-rated, large-cap growth stocks for your consideration. Big Cap 20 companies can deliver outsize gains without the volatility of smaller growth stocks. * View All IBD Big Cap 20 Stocks And Related Analysis | **Added To IBD Big Cap 20** | | | --- | --- | **Removed From IBD Big Cap 20** | | | Franco Nevada | (FNV) | Kratos Defense & Security Solutions | (KTOS) | | Kinder Morgan | (KMI) | Cloudflare Inc Cl A | (NET) | IPO Leaders ----------- Recent IPO stocks are where you often find some of the market's best stocks. New IPOs are typically in their early stages of growth, and it's big earnings growth that generally fuels a stock's price performance. IPO Leaders has special screening criteria to find up-and-coming stocks with strong fundamental and technical traits. * View All IPO Leaders Stocks And Related Analysis | **Added To IPO Leaders** | | | --- | --- | **Removed From IPO Leaders** | | | PayPay | (PAYP) | None | | Stock Spotlight --------------- This daily stock list seeks out the best stocks to buy and watch with top fundamentals that are getting ready to break out. Use it to glean emerging industry and sector trends in the market. * View All Stock Spotlight Stocks And Related Analysis | **Added To Stock Spotlight** | | | --- | --- | **Removed From Stock Spotlight** | | | Forgent Power Solutions | (FPS) | Aurinia Pharmaceuticals | (AUPH) | | Golar LNG | (GLNG) | Karman Holdings | (KRMN) | | Phibro Animal Health | (PAHC) | Ligand Pharmaceuticals | (LGND) | **View Prior IBD Stock Lists Updates** **_Please follow James DeTar on Twitter @JimDeTar_** **YOU MAY ALSO LIKE:** Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros MarketSmith's Tools Can Help The Individual Investor Profit From Short-Term Trends With SwingTrader Get Timely Buy & Sell Alerts With IBD Leaderboard How To Make Money In Stocks In 3 Simple Steps
ASML0,00%
TSM0,00%
PAYP0,00%
MDA0,00%
0
0
0
0
CoffeeNFTs

CoffeeNFTs

03-24 23:13
Keeping your watchlist up to date is key to making money in the stock market. IBD helps you do that by regularly updating stock screens like the IBD 50, IBD Big Cap 20, IPO Leaders and Stock Spotlight. In the tables below, you can see which stocks like aerospace play **Curtiss-Wright** (CW) have just been added to or removed from these lists. Aerospace and defense stocks are outperforming the market amid the U.S.-Iran-Israel war. Companies like Curtiss-Wright, **BWX Technologies** (BWXT), **MDA Space** (MDA), and **Karmen Holdings** (KRMN) are seeing sales and profits climb as the U.S. and other countries rush to resupply military gear. Meanwhile the pace of space exploration is picking up, giving the sector an added boost. ↑ X This video file cannot be played.(Error Code: 102630) Market Breadth: How This Indicator Reveals Hidden Weakness In A Bull Market See All Videos NOW PLAYING Market Breadth: How This Indicator Reveals Hidden Weakness In A Bull Market Another company on that list is **Kratos Defense and Security Solutions** (KTOS). It is among aerospace and defense companies developing next-generation hypersonic systems. These five are among a group of 24 outstanding stocks that rose onto various IBD top stock watchlists Monday. Each list helps identify the best stocks to buy and watch by using The IBD Methodology, which looks for stocks displaying the same common traits typically shared by the best-performing stocks in the early stages of their big price moves. Check this column daily to help build and maintain your watchlist with alerts to the most recent changes. Keep in mind that you should never buy a stock just because it's on an IBD list. Always do your own research and run all your stock ideas through a buying checklist. You can also streamline your investing process with IBD's simple three-step routine to quickly track general market trends, find stocks to watch, and pinpoint the best time to buy and sell. Changes made as of March 23, 2026 5:50 PM ET. IBD 50: Meet 10 New To the 50 ----------------------------- Aerospace firms BWX, Curtiss-Wright and MDA all came aboard IBD's flagship screen of the best growth stocks to watch. They joined AI stock Arista Networks and six others. The IBD 50 gives you 50 companies showing strong relative price strength and top-notch fundamentals. Before you decide what stocks to buy, always check out these new and innovative stocks that historically far outperform the S&P 500. * View All IBD 50 Stocks And Related Analysis * Check out the Innovator IBD 50 ETF (FFTY) | **Added To IBD 50** | | | --- | --- | **Removed From IBD 50** | | | Arista Networks | (ANET) | Burlington Stores | (BURL) | | BWX Technologies | (BWXT) | DHT Holdings | (DHT) | | Canadian Imperial Bank of Commerce | (CM) | Five Below | (FIVE) | | Curtiss-Wright | (CW) | Jabil | (JBL) | | Forgent Power Solutions | (FPS) | Kinder Morgan | (KMI) | | Hannon Armstrong Sustainable Infrastructure | (HASI) | Dorian LPG | (LPG) | | MDA Space | (MDA) | Lam Research | (LRCX) | | Macom | (MTSI) | Tenneco | (TEN) | | NAPCO Security Technologies | (NSSC) | Tradeweb Markets Cl A | (TW) | | SQM | (SQM) | ZTO Express | (ZTO) | IBD Newsletters --------------- #### Get exclusive IBD analysis and actionable news daily. SIGN UP NOW! IBD Newsletters --------------- #### Get exclusive IBD analysis and actionable news daily. * How To Invest * Market Prep * Tech Report Please enter a valid email address Please select a newsletter GO Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use x Thank You! ---------- #### You will now receive IBD Newsletters ALL DONE! Something Went Wrong! --------------------- #### Please contact customer service CLOSE IBD Sector Leaders ------------------ IBD's most stringent and powerful screen, IBD Sector Leaders highlight the best growth stocks in IBD's 33 sectors. All IBD Sector Leaders show outstanding earnings and sales growth in recent quarters and are strong across many other fundamental and price-performance metrics. * View All IBD Sector Leaders Stocks And Related Analysis | **Added To IBD Sector Leaders** | | | --- | --- | **Removed From IBD Sector Leaders** | | | None | | Taiwan Semiconductor | (TSM) | IBD Big Cap 20 -------------- This daily screen uncovers top-rated, large-cap growth stocks for your consideration. Big Cap 20 companies can deliver outsize gains without the volatility of smaller growth stocks. * View All IBD Big Cap 20 Stocks And Related Analysis | **Added To IBD Big Cap 20** | | | --- | --- | **Removed From IBD Big Cap 20** | | | EQT | (EQT) | Franco Nevada | (FNV) | | Jabil | (JBL) | Kinder Morgan | (KMI) | | Kratos Defense & Security Solutions | (KTOS) | Lam Research | (LRCX) | IPO Leaders: Karman In Hot Foursome ----------------------------------- Aerospace and defense firm Karmen says on its website that the "impossible ends here." Like Kratos, Karmen is involved in developing hypersonic rockets for the military. Karmen went public a little more than year ago, in February 2025. Recent IPO stocks are where you often find some of the market's best stocks. New IPOs are typically in their early stages of growth, and it's big earnings growth that generally fuels a stock's price performance. IPO Leaders has special screening criteria to find up-and-coming stocks with strong fundamental and technical traits. * View All IPO Leaders Stocks And Related Analysis | **Added To IPO Leaders** | | | --- | --- | **Removed From IPO Leaders** | | | Karman Holdings | (KRMN) | None | | | SOLV Energy | (MWH) | | | | Northpointe Bancshares | (NPB) | | | | Viking Holdings | (VIK) | | | Stock Spotlight --------------- This daily stock list seeks out the best stocks to buy and watch with top fundamentals that are getting ready to break out. Use it to glean emerging industry and sector trends in the market. * View All Stock Spotlight Stocks And Related Analysis | **Added To Stock Spotlight** | | | --- | --- | **Removed From Stock Spotlight** | | | Allient | (ALNT) | Andersons | (ANDE) | | Aurinia Pharmaceuticals | (AUPH) | Dell Technologies Cl C | (DELL) | | Ciena | (CIEN) | ESCO Technologies | (ESE) | | Okeanis Eco Tankers | (ECO) | Golar LNG | (GLNG) | | Comfort Systems USA | (FIX) | MasTec | (MTZ) | | Vista Energy | (VIST) | Phibro Animal Health | (PAHC) | | Viasat | (VSAT) | Vertiv Holdings | (VRT) | **View Prior IBD Stock Lists Updates** _Please follow James DeTar on Twitter @JimDeTar_ **YOU MAY ALSO LIKE:** Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros MarketSmith's Tools Can Help The Individual Investor Profit From Short-Term Trends With SwingTrader Get Timely Buy & Sell Alerts With IBD Leaderboard How To Make Money In Stocks In 3 Simple Steps
MDA0,00%
TSM0,00%
SOLV+0,34%
0
0
0
0